Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Licenses Technology From RiboTask

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDRNA today said it has acquired the exclusive rights to develop, make, use, and sell unlocked nucleobase analog-based diagnostics from RiboTask.

The agreement expands a previous agreement between the two firms for exclusive rights to develop UsiRNA-based therapeutics. As a result of today's announcement and previously obtained exclusive rights to conformationally restricted nucleotide technology for both therapeutics and diagnostics, MDRNA now has one of the few intellectual property portfolios that support a nucleic acid-based personalized medicine platform and the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics, the Bothell, Wash., firm said in a statement.

Ribotask, a privately owned Danish firm, which develops and synthesizes RNA chemistries, keeps co-exclusive right to manufacture, sell, and sublicense UNA technology for reagents development.

Financial terms of the deal were not disclosed.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.